Hyperoxaluria, Primary clinical trials
The registry lists 44 studies for Hyperoxaluria, Primary across more than 10 countries. 12 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-23.
Status
- Completed
- 23
- Recruiting
- 11
- Active, not recruiting
- 2
- Withdrawn
- 2
- Status unknown
- 2
- Terminated
- 2
Phase
- Phase 2
- 12
- Phase 3
- 10
- Phase 1
- 7
- Early Phase 1
- 2
Where
- United States
- 25
- Germany
- 18
- United Kingdom
- 14
- France
- 13
- Netherlands
- 8
- Israel
- 5
Who runs them
Mayo Clinic (9) · OxThera (6) · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (6) · Alnylam Pharmaceuticals (5) · Biocodex (2) · YolTech Therapeutics Co., Ltd (2) · Hospices Civils de Lyon (2) · Ann & Robert H Lurie Children's Hospital of Chicago (1)
Studies
Recruiting first, then most recently updated. Showing 44 of 44 — search for more.
- Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)RecruitingNCT07587021Phase 21 country
- Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1)RecruitingNCT07776626Phase 11 country
- Prospective Research Rare Kidney Stones (ProRKS)RecruitingNCT027802974 countries
- Rare Kidney Stone Consortium BiobankRecruitingNCT020263881 country
- Rare Kidney Stone Consortium Patient RegistryRecruitingNCT005885622 countries
- Monogenic Kidney Stone - Genetic TestingRecruitingNCT033058351 country
- Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)RecruitingNCT06839235Phase 1/25 countries
- Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)RecruitingNCT06511349Early Phase 11 country
- Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3Not yet recruitingNCT06465472Phase 3
- Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.RecruitingNCT062258821 country
- National Registry of Rare Kidney DiseasesRecruitingNCT060658521 country
- Genetic Newborn Screening for Cystinosis and Primary HyperoxaluriaRecruitingNCT05843851Not applicable1 country
- Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal FunctionCompletedNCT05001269Phase 211 countries
- Baby Detect : Genomic Newborn ScreeningCompletedNCT056874741 country
- A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1CompletedNCT04152200Phase 311 countries
- Long Term Extension Study in Patients With Primary HyperoxaluriaActive, not recruitingNCT04042402Phase 313 countries
- Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)Active, not recruitingNCT06892301Early Phase 11 country
- A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1CompletedNCT03905694Phase 35 countries
- Natural History of Patients With PH3 and a History of Stone EventsCompletedNCT045425905 countries
- Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary HyperoxaluriaCompletedNCT03392896Phase 15 countries
- Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 PatientsCompletedNCT04555486Phase 14 countries
- A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1CompletedNCT03681184Phase 38 countries
- A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)TerminatedNCT02795325Phase 12 countries
- Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1Approved for marketingNCT04125472
- Health-related Quality of Life in Rare Kidney StoneCompletedNCT021243952 countries
- Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on DialysisCompletedNCT02000219Phase 21 country
- A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary HyperoxaluriaCompletedNCT03116685Phase 37 countries
- An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary HyperoxaluriaTerminatedNCT03938272Phase 36 countries
- Phenotyping of Primary HyperoxaluriaStatus unknownNCT051078301 country
- Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary HyperoxaluriaCompletedNCT03819647Phase 21 country
- Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and HyperoxalemiaCompletedNCT03391804Phase 23 countries
- Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1CompletedNCT02706886Phase 1/25 countries
- Primary Hyperoxaluria Mutation Genotyping/PhenotypingCompletedNCT023406891 country
- Proteomics of Primary Hyperoxaluria Type 1CompletedNCT03067142
- Descriptive Analysis of Gut Microbiome Alterations in Hyperoxaluric PatientsStatus unknownNCT027946491 country
- IDENTIFICATION OF A MULTI-ANALYTE PROFILE FOR PRIMARY HYPEROXALURIA AND COMPARISON WITH HEALTHY SIBLINGS AND IDIOPATHIC HYPERCALCIURIACompletedNCT02830009Not applicable1 country
- Primary Hyperoxaluria Mutation GenotypingCompletedNCT005892251 country
- Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary HyperoxaluriaCompletedNCT02012985Phase 1/23 countries
- International Registry for Primary HyperoxaluriaWithdrawnNCT008758231 country
- Renal Protective Effect of ACEI and ARB in Primary HyperoxaluriaWithdrawnNCT00280215Phase 3
- Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary HyperoxaluriaCompletedNCT00283387Phase 21 country
- Phase 2/3 Oxabact StudyCompletedNCT01037231Phase 2/33 countries
- Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria PatientsCompletedNCT00638703Phase 2/31 country
- Trial on Treatment of Patients With Primary Hyperoxaluria Type I With Pyridoxal-phosphateCompletedNCT01281878Phase 21 country